ASTRIVAX
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
ASTRIVAX
Industry:
Clinical Trials Medical
Founded:
2022-01-01
Address:
Heverlee, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.astrivax.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
35.5 M EUR
Technology used in webpage:
CrUX Top 50m CrUX Dataset COVID-19
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
EGenesis
EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
LyGenesis
LyGenesis is an organ regeneration company that facilitates organ regeneration and transplant.
Pepgen
PepGen is empowering nucleic acid therapeutics to go the distance.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Investors List
Agentschap Innoveren & Ondernemen
Agentschap Innoveren & Ondernemen investment in Grant - AstriVax
Agentschap Innoveren & Ondernemen
Agentschap Innoveren & Ondernemen investment in Grant - AstriVax
Fund+
Fund+ investment in Seed Round - AstriVax
BNP Paribas Fortis
BNP Paribas Fortis investment in Seed Round - AstriVax
Flanders Future Techfund
Flanders Future Techfund investment in Seed Round - AstriVax
Mérieux Equity Partners
Mérieux Equity Partners investment in Seed Round - AstriVax
Thuja Capital
Thuja Capital investment in Seed Round - AstriVax
V-Bio Ventures
V-Bio Ventures investment in Seed Round - AstriVax
Ackermans & van Haaren
Ackermans & van Haaren investment in Seed Round - AstriVax
Gemma Frisius Fund
Gemma Frisius Fund investment in Seed Round - AstriVax
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-10 | AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag |
Official Site Inspections
http://www.astrivax.com Semrush global rank: 14.03 M Semrush visits lastest month: 64
- Host name: 185.86.18.125.hosted.by.stone-is.net
- IP address: 185.86.18.125
- Location: Belgium
- Latitude: 50.8509
- Longitude: 4.3447
- Timezone: Europe/Brussels
More informations about "AstriVax"
AstriVax - Crunchbase Company Profile & Funding
Additionally, AstriVax is included in the portfolio of Growth Capital, which is a core sector, indicating that it has attracted significant investment interest. Furthermore, the company's presence in Belgium, as mentioned in an author's present …See details»
AstriVax - LinkedIn
AstriVax | 2,833 followers on LinkedIn. Committed to address real-world challenges in vaccinology | AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on ...See details»
AstriVax Company Profile 2024: Valuation, Funding & Investors
AstriVax General Information Description. Developer of novel vaccines designed to address real-world challenges in vaccinology. The company's vaccines specialize in reducing cold chain …See details»
AstriVax Company Profile: Overview and Full News Analysis
AstriVax is a privately held Belgian company founded in 2022, located in Vlaams-Brabant, specifically in Haasrode (Leuven). The company was established based on vaccine …See details»
Astrivax Company Profile | Leuven, Vlaams Brabant, Belgium ...
Find company research, competitor information, contact details & financial data for Astrivax of Leuven, Vlaams Brabant. Get the latest business insights from Dun & Bradstreet.See details»
AstriVax - EU-Startups
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. Based on vaccination technologies created at the Rega Institute and …See details»
AstriVax, une spin-off de la KU Leuven, lève 30 millions EUR pour ...
AstriVax, une spin-off de la KU Leuven, lève 30 millions EUR pour construire une plateforme de vaccins. Louvain, Belgique, le 25 août 2022 – Avec 30 millions EUR, AstriVax a levé le plus …See details»
KU Leuven spin-off AstriVax raises € 30 million seed capital to …
Leuven, Belgium, 25 August 2022 – Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs.The company will draw on …See details»
KU Leuven spin-off AstriVax raises € 30 million to build vaccine ...
Aug 25, 2022 Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs. The company will draw on technology developed at the KU …See details»
AstriVax raises $30 million to build vaccine platform
Aug 25, 2022 AstriVax, a start-up working to develop novel vaccines, has raised the largest amount of seed capital in the history of Belgium-based university KU Leuven spin-offs, totalling …See details»
KU Leuven spin-off AstriVax raises € 30 million to build ... - LinkedIn
Aug 25, 2022 ViroVet is impressed and very pleased to see Astrivax raising an amazing 30 million euro to develop human vaccines using the same vaccine platform ViroVet using for its …See details»
AstriVax - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... AstriVax is a vaccine platform …See details»
AstriVax: thermostable, plug-and-play vaccines using plasmids
Sep 26, 2022 Backed by V-Bio Ventures and Fund+, AstriVax is aiming to reduce the cold chain requirements and simplify manufacturing of live-attenuated virus vaccines with its plug-and …See details»
KU Leuven spin-off AstriVax raises € 30 million to build vaccine ...
Leuven, Belgium, 25 August 2022 – Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs. The company will draw on …See details»
AstriVax, an innovative vaccine platform company ... - Benzinga
Mar 24, 2023 Emmanuel Hanon, PhD, will chair the company's scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD, PhD) have been …See details»
AVX 70481 - AdisInsight - Springer
Jun 28, 2024 AVX 70481 is a plasmid DNA based live attenuated rabies virus vaccine being developed by AstriVax (a spin out of KU Leuven) utilising PLLAV platform technology. AVX …See details»
AstriVax - Company Profile - Tracxn
May 30, 2024 Competitive landscape of AstriVax AstriVax has a total of 420 competitors and it ranks 48 th among them. 104 of its competitors are funded while 79 have exited. Overall, …See details»
AstriVax - Raised $29.9M Funding from 9 investors - Tracxn
Dec 5, 2024 AstriVax has raised a total funding of $29.9M over 3 rounds from 9 investors. Investors include Merieux Equity Partners, Thuja Capital and 7 others. Their latest funding …See details»